Overview and Scope
Soft tissue sarcoma refers to a disease where cancer cells form in the soft tissues of the body which can be diagnosed through biopsy techniques. It is commonly caused in tissues including blood arteries, muscle, neurons, and fat.
Sizing and Forecast
The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $2.87 billion in 2023 to $3.13 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited treatment options, evolving understanding of sarcoma biology, growth in cancer research funding, rising prevalence of soft tissue sarcoma, expansion of healthcare infrastructure.
The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $4.3 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to development of targeted therapies for soft tissue sarcoma, increasing focus on personalized medicine, expansion of clinical trials for sarcoma treatments, growing awareness and early detection initiatives,. Major trends in the forecast period include integration of immunotherapy in soft tissue sarcoma treatment, development of combination therapies, emphasis on patient-centric care models, rise in the use of liquid biopsies, advances in sarcoma genomics.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/soft-tissue-sarcoma-global-market-report
Segmentation & Regional Insights
The soft tissue sarcoma market covered in this report is segmented –
1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
North America was the largest region in the soft tissue sarcoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12211&type=smp
Major Driver Impacting Market Growth
The surge in cancer incidence is expected to propel the growth of the soft tissue sarcoma market going forward. Cancer is a broad category of illnesses that can develop in any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The rise in cancer incidence increases the need for diagnostic procedures, therapeutic regimens, and supportive care choices to meet the unique requirements of patients with several types of cancer or sarcoma, which boosts the market for soft tissue sarcomas. For instance, in 2021, According to the American cancer society, 1.8 million new cancer cases diagnosed in 2020. Furthermore, according to September 2020 data published by the National Cancer Institute, a US-based government agency part of the National Institutes of Health, 1,806,590 new cancer cases were recorded, indicating that 43% of all cancer diagnosed in men in the United States in 2020, up from 1,752,735 in the previous year, i.e., 2019. Therefore, the surge in cancer incidence is driving the growth of the soft tissue sarcoma market.
Key Industry Players
Major companies operating in the soft tissue sarcoma market report are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.
The soft tissue sarcoma market report table of contents includes:
1. Executive Summary
2. Soft Tissue Sarcoma Market Characteristics
3. Soft Tissue Sarcoma Market Trends And Strategies
4. Soft Tissue Sarcoma Market – Macro Economic Scenario
5. Global Soft Tissue Sarcoma Market Size and Growth
…
32. Global Soft Tissue Sarcoma Market Competitive Benchmarking
33. Global Soft Tissue Sarcoma Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Soft Tissue Sarcoma Market
35. Soft Tissue Sarcoma Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
